Apogee Therapeutics to Host Inaugural Virtual R&D Day on December 2, 2024
Apogee Therapeutics (Nasdaq: APGE) has announced its inaugural virtual R&D Day, scheduled for December 2, 2024, at 10:00 a.m. ET. The event will showcase the company's progress in developing novel biologics for inflammatory and immunology (I&I) conditions, including atopic dermatitis, asthma, and chronic obstructive pulmonary disease.
The presentation will feature management updates focusing on APG777's potential in atopic dermatitis treatment, combination therapy strategies, and commercial opportunities in I&I markets. Key opinion leaders will discuss the current treatment landscape and emerging opportunities for patients with these conditions.
Apogee Therapeutics (Nasdaq: APGE) ha annunciato il suo primo R&D Day virtuale, programmato per il 2 dicembre 2024, alle 10:00 ET. L'evento metterà in mostra i progressi dell'azienda nello sviluppo di nuovi biologici per le condizioni infiammatorie e immunologiche (I&I), comprese la dermatite atopica, l'asma e la broncopneumopatia cronica ostruttiva.
La presentazione includerà aggiornamenti della dirigenza focalizzati sul potenziale di APG777 nel trattamento della dermatite atopica, strategie di terapia combinata e opportunità commerciali nei mercati I&I. I leader di opinione discuteranno dell'attuale panorama terapeutico e delle opportunità emergenti per i pazienti con queste condizioni.
Apogee Therapeutics (Nasdaq: APGE) ha anunciado su primer Día Virtual de I+D, programado para el 2 de diciembre de 2024, a las 10:00 a.m. ET. El evento mostrará el progreso de la empresa en el desarrollo de nuevos biológicos para condiciones inflamatorias e inmunológicas (I&I), incluyendo dermatitis atópica, asma y enfermedad pulmonar obstructiva crónica.
La presentación contará con actualizaciones de la dirección enfocadas en el potencial de APG777 en el tratamiento de la dermatitis atópica, estrategias de terapia combinada y oportunidades comerciales en los mercados de I&I. Los líderes de opinión clave discutirán el panorama actual de tratamientos y las oportunidades emergentes para los pacientes con estas condiciones.
Apogee Therapeutics (Nasdaq: APGE)는 2024년 12월 2일 오전 10시(동부 표준시)에 예정된 최초의 가상 연구 개발(R&D) 데이를 발표했습니다. 이번 행사는 아토피 피부염, 천식, 만성 폐쇄성 폐질환을 포함한 염증 및 면역학(I&I) 질환을 위한 새로운 생물학적 제제 개발에 대한 회사의 진전을 보여줄 것입니다.
발표에서는 APG777의 잠재력에 대한 경영진 업데이트가 포함되어 아토피 피부염 치료, 병용 요법 전략 및 I&I 시장의 상업적 기회에 초점을 맞출 것입니다. 주요 의견 리더들은 현재의 치료 환경과 이러한 질병을 가진 환자를 위한 새로운 기회에 대해 논의할 것입니다.
Apogee Therapeutics (Nasdaq: APGE) a annoncé son premier R&D Day virtuel, prévu pour le 2 décembre 2024 à 10h00 (heure de l'Est). L'événement mettra en avant les progrès de l'entreprise dans le développement de nouveaux biologiques pour des affections inflammatoires et immunologiques (I&I), y compris la dermatite atopique, l'asthme et la maladie pulmonaire obstructive chronique.
La présentation comprendra des mises à jour de la direction axées sur le potentiel d'APG777 dans le traitement de la dermatite atopique, des stratégies de thérapie combinée et des opportunités commerciales sur les marchés I&I. Des leaders d'opinion clés discuteront de l'environnement thérapeutique actuel et des opportunités émergentes pour les patients souffrant de ces conditions.
Apogee Therapeutics (Nasdaq: APGE) hat seinen ersten virtuellen F&E-Tag angekündigt, der für den 2. Dezember 2024 um 10:00 Uhr ET geplant ist. Die Veranstaltung wird die Fortschritte des Unternehmens bei der Entwicklung neuer biologischer Präparate für entzündliche und immunologische (I&I) Erkrankungen, einschließlich atopischer Dermatitis, Asthma und chronisch obstruktiver Lungenerkrankung, präsentieren.
Die Präsentation wird Management-Updates enthalten, die sich auf das Potential von APG777 bei der Behandlung der atopischen Dermatitis, Kombinationstherapien und kommerzielle Möglichkeiten auf den I&I-Märkten konzentrieren. Schlüsselfiguren werden die aktuelle Behandlungssituation und aufkommende Möglichkeiten für Patienten mit diesen Erkrankungen erörtern.
- None.
- None.
Company to highlight progress across its pipeline and showcase its path to reshaping the standard of care in I&I with best-in-class monotherapy and combination treatments
SAN FRANCISCO and WALTHAM, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD) and other I&I indications, today announced that it will host its virtual R&D Day at 10:00 a.m. ET on Monday, December 2, 2024.
The event will include presentations from management discussing updates across Apogee’s programs, highlighting APG777’s best-in-class potential in AD, the significant role of combinations to drive deeper, longer-term responses and the broad commercial opportunity in I&I indications for programs that offer transformational efficacy and dosing. The company will also host key opinion leader guest speakers from the I&I space discussing the current landscape and need for new treatment opportunities for patients living with these conditions.
To join the webcast, please visit this link, or the News & Events page of the Investors section on the Company’s website https://apogeetherapeutics.com. A replay of the webcast will be archived and available following the event.
About Apogee
Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. APG777, the company’s most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&I markets. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the company believes it can deliver value and meaningful benefit to patients underserved by today’s standard of care. For more information, please visit https://apogeetherapeutics.com.
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
dan@1abmedia.com
FAQ
When is Apogee Therapeutics (APGE) hosting its first R&D Day?
What therapeutic areas will be discussed at Apogee's (APGE) R&D Day 2024?
What is APG777 being developed for by Apogee (APGE)?
How can investors access Apogee's (APGE) R&D Day presentation?
